Back to Interventions

Substance / Medication

Phenmetrazine

SNOMED 387127002 UMLS C0031411

Overview

Active Ingredient

phenmetrazine

RxNorm CUI

8133

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

LOINC 2093-3

secondary

LOINC 4549-2

secondary

LOINC 2571-8

secondary

Clinical Trials

426 trials linked to this intervention

426

Total Trials

122

Recruiting

109

With Results

Recent Trials

Diabetes and Heart Disease Risk in Blacks

NCT00001853Recruiting2000 enrolled

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

NCT00009555Phase 4Completed86 enrolled

Pediatric Hypothalamic Obesity

NCT00076362Phase 4Completed60 enrolled

The Safety and Effectiveness of Low and High Carbohydrate Diets

NCT00079547Phase 4Completed307 enrolled

Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity

NCT00134303Phase 4Completed65 enrolled

View all 426 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM).

Grumann Christina, Huppertz Laura M, Bisel Philippe et al. · Drug Test Anal · 2019

PMID: 30784204Observational

Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine.

Lehmann Sabrina, Sczyslo Alissa, Froch-Cortis Judith et al. · Forensic Sci Int · 2019

PMID: 31546164Case Report

Novel psychoactive substances: overdose of 3-fluorophenmetrazine (3-FPM) and etizolam in a 33-year-old man.

Benesch Matthew G K, Iqbal Sahar J · BMJ Case Rep · 2018

PMID: 29884719Case ReportFull text (PMC)

Multiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700.

Ellefsen Kayla N, Taylor Elizabeth A, Simmons Paul et al. · J Anal Toxicol · 2017

PMID: 28985320Case Report

Toxicokinetics and analytical toxicology of the phenmetrazine-derived new psychoactive substance 3,4-methylenedioxyphenmetrazine studied by means of in vitro systems.

Kroesen Matthias D, Gampfer Tanja M, Wagmann Lea et al. · Arch Toxicol · 2025

PMID: 39903277OtherFull text (PMC)

Chronic phenmetrazine treatment promotes Ddopaminergic and α2-adrenergic receptor desensitization and alters phosphorylation of signaling proteins and local cerebral glucose metabolism in the rat brain.

Keegan Bradley M, Dreitzler Annie L, Sexton Tammy et al. · Brain Res · 2021

PMID: 33631209OtherFull text (PMC)

Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications.

Jiang Ying, Murnane Kevin S, Bhattaccharjee Sonalika A et al. · AAPS J · 2019

PMID: 31152318Other

Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers.

McLaughlin Gavin, Morris Noreen, Kavanagh Pierce V et al. · Drug Test Anal · 2017

PMID: 26810957Other

Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers.

McLaughlin Gavin, Baumann Michael H, Kavanagh Pierce V et al. · Drug Test Anal · 2018

PMID: 29673128PreclinicalFull text (PMC)

Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family.

Mayer Felix P, Burchardt Nadine V, Decker Ann M et al. · Neuropharmacology · 2018

PMID: 28988906PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Obesity Medicine (Family Medicine) Physician

Family Medicine — Obesity Medicine

NUCC 207QB0002X

Obesity Medicine (Internal Medicine) Physician

Internal Medicine — Obesity Medicine

NUCC 207RB0002X

Endocrinology, Diabetes & Metabolism Physician

Internal Medicine — Endocrinology, Diabetes & Metabolism

NUCC 207RE0101X

Find a Provider

Health Goals

Goals connected through associated conditions

Manage Weight and Body Composition Optimize Metabolic Function

Quick Facts

Type: Substance / Medication
Fully Specified Name: Phenmetrazine (substance)
SNOMED CT: 387127002
UMLS CUI: C0031411
RxNorm CUI: 8133

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

1

Conditions

3

Biomarkers

3

Specialists

0

Symptoms

426

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.